Imvigor011 Bladder Cancer Trial Achieves Positive Results, With Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Natera Inc NTRA.O:
IMVIGOR011 BLADDER CANCER TRIAL ACHIEVES POSITIVE RESULTS, WITH SIGNATERA™ STRONGLY PREDICTING ADJUVANT IMMUNOTHERAPY BENEFIT
NATERA INC - SIGNATERA-POSITIVE PATIENTS SHOW IMPROVED SURVIVAL WITH ATEZOLIZUMAB
NATERA INC - TO FINALIZE FDA APPLICATION FOR SIGNATERA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.